Abstract
Klebsiella pneumoniae is associated with high resistance to antimicrobials and is common in isolates from colonization and healthcare-associated infections (HAIs). This study aims to develop assays to detect resistance genes belonging to the bla family and investigate metabolic pathways in resistant isolates of K. pneumoniae. The genes of the subfamilies included were: blaSHV, bla TEM, blaNDM, blaKPC, bla GES, bla CTX-M and relevant variants of the blaOXA subfamily. Mass spectrometry data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Isolates of K. pneumoniae (N = 122) were obtained from clinical samples from 04/23/2019 to 05/29/2021. A high prevalence of resistance to penicillins, cephalosporins and carbapenems was found among the isolates. The identified genotypic profile showed a high prevalence of genes belonging to Ambler’s classes of beta-lactamases A, B and D. In the metabolomic study, the N-fructosyl isoleucine metabolite was identified increased in multidrug-resistant (MDR) strains of K. pneumoniae compared to strains susceptible to antimicrobials. In conclusion, the assays developed were efficient in detecting the main genes of the bla family of resistance in K. pneumoniae. The use of the pentose phosphate metabolic pathway suggests a beneficial regulation of bacterial growth, and colonization in MDR K. pneumoniae strains, with may indicate the use of this pathway as a virulence mechanism in resistant strains.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by by CNPq (http://www.cnpq.br), grant numbers 402607/2018-0 and 408549/2022-0. And FUNCAP (https://www.funcap.ce.gov.br/), grant number: OFíCIO no. 102/2021 - DINOV.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Brazilian National Research Ethics Commission gave ethical approval for this work. Approval number (no. 03300218.2.0000.5054).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
An adjustment was made to the title for better correlation with the work data.
Data Availability Statement
The data and reports relating to this study will be available via direct request via email to the corresponding author.
